| Literature DB >> 35322049 |
Natalia Kurhaluk1, Halyna Tkachenko2.
Abstract
Imbalanced glucose tolerance and insulin resistance remain important as high cancer risk factors. Metformin administration to diabetic patients may be associated with a reduced risk of malignancy. The combined effects of the hormone melatonin and metformin in oncology practice have shown positive results. The relevance of our study is to find out the role of specific biomarkers of lysosome destruction and oxidative stress data in carcinogenesis models. The present study was designed to investigate the comparative synergic effect of peroral antidiabetic metformin (MF) and pineal hormone melatonin (MEL) administered alone and in combination in two different rat's models of mammary tumour proliferation in vivo (N-methyl-N-nitrosourea, NMU or 7,12-dimethylbenz[a]anthracene, DMBA). We have studied the processes of lysosomal destruction (alanyl aminopeptidase AAP, leucyl aminopeptidase LAP, acid phosphatase AcP, β-N-acetylglucosaminidase NAG, β-galactosidase β-GD and β-glucuronidase β-GR) caused by evaluated oxidative stress in three types of tissues (liver, heart, and spleen) in female Sprague-Dawley rats fed a high-fat diet (10% of total fat: 2.5% from lard and 7.5% from palm olein). Our results revealed an increase in the activity of the studied lysosomal enzymes and their expression in a tissue-specific manner depending on the type of chemical agent (NMU or DMBA). MANOVA tests in our study confirmed the influence of the three main factors, type of tissue, chemical impact, and chemopreventive agents, and the combinations of these factors on the lysosomal activity induced during the process of cancerogenesis. The development and induction of the carcinogenesis process in the different rat models with the high-fat diet impact were also accompanied by initiation of free-radical oxidation processes, which we studied at the initial (estimated by the level of diene conjugates) and final (TBARS products) stages of this process. The combined effects of MEL and MF for the two models of carcinogenesis at high-fat diet impact for AAP, LAP, and AcP showed a significant synergistic effect when they impact together when compared with the effects of one substance alone (either MEL or MF) in the breast cancer model experiments. Synergistic effects of limiting destructive processes of lysosomal functioning β-GD enzyme activity we obtained in experiments with MEL and MF chemoprevention for both models of carcinogenesis for three tissues. The statistical SS test allowed us to draw the following conclusions on the role of each lysosomal parameter analyzed as an integral model: NAG > AcP > β-GD > β-GR > AAP > LAP.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35322049 PMCID: PMC8943031 DOI: 10.1038/s41598-022-08778-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Effect of melatonin and metformin on alanyl- and leucyl aminopeptidase activity (nmol h−1 mg−1 protein) in the liver, heart, and spleen in female Sprague-Dawley rats subjected to a high-fat diet in the mammary carcinogenesis model induced by N-methyl-N-nitrosourea (NMU) or dimethylbenzanthracene (DMBA). Metformin (MF) or melatonin (MEL) was administered alone and in combination (MF + MEL).
| Parameters/ | Liver | Heart | Spleen | Liver | Heart | Spleen |
|---|---|---|---|---|---|---|
| AAP, nmol h−1 mg−1 protein | LAP, nmol h−1 mg−1 protein | |||||
| Control | 799.88 ± 167.48 | 166.69 ± 25.9 | 121.82 ± 8.63 | 55.17 ± 7.70 | 221.79 ± 20.11 | 241.69 ± 20.14 |
| NMU | 976.10 ± 135.39 | 178.3 ± 21.25 | 158.44 ± 19.31a | 152.21 ± 25.41a | 236.33 ± 38.95 | 264.17 ± 31.12 |
| DMBA | 1078.33 ± 218.20 | 241.14 ± 20.14aa | 148.54 ± 16.18aa | 146.20 ± 32.01aa | 258.01 ± 28.21 | 274.95 ± 31.12 |
| MF + NMU | 1016.80 ± 190.60 | 212.46 ± 45.14 | 155.20 ± 26.18 | 116.85 ± 7.89b | 237.92 ± 20.47 | 255.92 ± 29.49 |
| MF + DMBA | 845.56 ± 198.12 | 201.52 ± 25.4 | 138.95 ± 22.41 | 101.25 ± 11.20 | 244.50 ± 24.69 | 258.72 ± 19.49 |
| MEL + NMU | 968.19 ± 144.58 | 285.11 ± 68.31c | 174.31 ± 26.29 | 118.25 ± 9.58c | 232.16 ± 18.72 | 232.16 ± 21.10 |
| MEL + DMBA | 985.22 ± 214.02 | 265.21 ± 33.01cc | 154.22 ± 47.9 | 98.47 ± 9.52cc | 219.33 ± 23.01 | 255.92 ± 39.49 |
| MF + MEL + NMU | 946.50 ± 134.96 | 213.43 ± 35.42e | 121.82 ± 17.96e | 121.11 ± 10.21 | 242.11 ± 33.01 | 232.01 ± 17.05 |
| MF + MEL + DMBA | 857.23 ± 158.12 | 190.47 ± 24.11ee | 132.15 ± 17.91 | 78.04 ± 8.21dd | 199.07 ± 17.58 | 199.66 ± 18.47dd |
Note. Data are expressed as means ± S.D.
Significant differences P < 0.05 are designated as follows: a—NMU group vs. control group; aa—DMBA group vs. control group; b—MF + NMU vs. NMU group; bb—MF + DMBA vs. DMBA group; c—MEL + NMU vs. NMU group; cc—MEL + DMBA vs. DMBA group; d—MEL + MF + NMU vs. MF + NMU group; dd—MEL + MF + DMBA vs. MF + DMBA group; e—MEL + MF + NMU vs. MEL + NMU group; ee—MEL + MF + DMBA vs. MEL + DMBA group.
AAP, alanyl aminopeptidase; LAP, leucyl aminopeptidase.
NMU, N-methyl-N-nitrosourea; DMBA, dimethylbenzanthracene; MF, metformin; MEL, melatonin.
Effect of melatonin and metformin on acid phosphatase and β-N-acetylglucosaminidase activity (nM/h/mg protein) in the liver, heart and spleen in female Sprague-Dawley rats subjected to a high-fat diet in the mammary carcinogenesis model induced by N-methyl-N-nitrosourea (NMU) or dimethylbenzanthracene (DMBA). Metformin (MF) or melatonin (MEL) was administered alone and in combination (MF + MEL).
| Parameters/ | Liver | Heart | Spleen | Liver | Heart | Spleen |
|---|---|---|---|---|---|---|
| AcP, nmol h−1 mg−1 protein | NAG, nmol h−1 mg−1 protein | |||||
| Control | 572.65 ± 67.49 | 603.00 ± 49.86 | 280.83 ± 37.98 | 255.23 ± 37.73 | 582.13 ± 40.34 | 205.05 ± 2.14 |
| NMU | 1036.33 ± 105.21a | 596.58 ± 68.31 | 458.04 ± 39.31a | 770.63 ± 55.41a | 693.28 ± 51.14a | 310.25 ± 11.92a |
| DMBA | 1241.78 ± 109.16aa | 641.18 ± 68.31 | 378.54 ± 46.18aa | 684.03 ± 52.01aa | 593.12 ± 69.62 | 245.95 ± 23.20aa |
| MF + NMU | 916.52 ± 128.41 | 740.42 ± 65.14 | 425.22 ± 56.18 | 530.11 ± 47.89b | 687.16 ± 42.47 | 283.94 ± 23.82 |
| MF + DMBA | 878.56 ± 98.12bb | 630.52 ± 85.40 | 338.04 ± 42.41 | 608.25 ± 11.20 | 736.14 ± 54.69bb | 208.42 ± 19.47 |
| MEL + NMU | 903.19 ± 84.57 | 721.23 ± 58.41 | 338.31 ± 46.29 | 682.25 ± 59.48 | 778.91 ± 58.72 | 255.78 ± 30.10 |
| MEL + DMBA | 985.21 ± 94.02cc | 665.24 ± 83.08 | 424.22 ± 57.9 | 498.47 ± 19.52cc | 719.33 ± 43.01 | 187.16 ± 10.49cc |
| MF + MEL + NMU | 711.50 ± 84.96d | 643.48 ± 35.42 | 229.82 ± 19.92d,e | 444.32 ± 40.21d,e | 504.26 ± 43.01d,e | 139.58 ± 17.05d,e |
| MF + MEL + DMBA | 749.23 ± 58.18dd,ee | 590.41 ± 74.11 | 242.18 ± 34.91dd,ee | 382.14 ± 48.21dd,ee | 521.45 ± 57.58dd,ee | 147.21 ± 18.07dd |
Note. Data are expressed as means ± S.D.
Significant differences P < 0.05 are designated as follows: a—NMU group vs. control group; aa—DMBA group vs. control group; b—MF + NMU vs. NMU group; bb—MF + DMBA vs. DMBA group; c—MEL + NMU vs. NMU group; cc—MEL + DMBA vs. DMBA group; d—MEL + MF + NMU vs. MF + NMU group; dd—MEL + MF + DMBA vs. MF + DMBA group; e—MEL + MF + NMU vs. MEL + NMU group; ee—MEL + MF + DMBA vs. MEL + DMBA group.
AcP, acid phosphatase; NAG, β-N-acetylglucosaminidase.
NMU, N-methyl-N-nitrosourea; DMBA, dimethylbenzanthracene; MF, metformin; MEL, melatonin.
Effect of melatonin and metformin on β-glucuronidase and β-galactosidase activity (nM/h/mg protein) in the liver, heart and spleen in female Sprague-Dawley rats subjected to a high-fat diet in the mammary carcinogenesis model induced by N-methyl-N-nitrosourea (NMU) or dimethylbenzanthracene (DMBA). Metformin (MF) or melatonin (MEL) was administered alone and in combination (MF + MEL).
| Parameters/ | Liver | Heart | Spleen | Liver | Heart | Spleen |
|---|---|---|---|---|---|---|
| β-GD, nmol h−1 mg−1 protein | β-GR, nmol h−1 mg−1 protein | |||||
| Control | 313.06 ± 67.48 | 186.02 ± 17.58 | 184.73 ± 1.63 | 317.40 ± 45.70 | 62.24 ± 6.01 | 200.15 ± 2.14 |
| NMU | 575.14 ± 40.39a | 180.57 ± 21.25 | 163.60 ± 21.14 | 613.04 ± 45.41a | 102.80 ± 8.75a | 177.28 ± 31.12 |
| DMBA | 478.66 ± 78.20aa | 194.33 ± 22.14 | 170.07 ± 25.44 | 675.45 ± 112.01aa | 132.81 ± 8.41aa | 184.32 ± 21.17 |
| MF + NMU | 490.24 ± 50.60 | 214.76 ± 21.40 | 275.21 ± 24.18b | 535.45 ± 57.89 | 77.41 ± 6.47b | 259.09 ± 25.41b |
| MF + DMBA | 465.22 ± 58.12 | 198.22 ± 15.41 | 247.51 ± 32.41bb | 455.87 ± 71.20 | 84.25 ± 8.69bb | 214.21 ± 33.25 |
| MEL + NMU | 443.52 ± 64.58c | 209.52 ± 62.11 | 225.19 ± 36.01 | 575.84 ± 58.58 | 57.54 ± 8.42 | 239.11 ± 21.78 |
| MEL + DMBA | 585.02 ± 74.02cc | 205.21 ± 17.01 | 337.04 ± 47.91cc | 498.47 ± 62.52 | 51.25 ± 5.01cc | 205.63 ± 19.09 |
| MF + MEL + NMU | 317.70 ± 44.96d,e | 168.33 ± 15.42d | 188.39 ± 17.96d | 387.52 ± 60.21d,e | 55.90 ± 3.09d | 177.64 ± 17.05d |
| MF + MEL + DMBA | 314.08 ± 18.12ee | 162.58 ± 24.17 | 172.15 ± 17.91ee | 390.54 ± 68.21 | 53.40 ± 5.58dd | 162.24 ± 21.47 |
Note. Data are expressed as means ± S.D.
Significant differences P < 0.05 are designated as follows: a—NMU group vs. control group; aa—DMBA group vs. control group; b—MF + NMU vs. NMU group; bb—MF + DMBA vs. DMBA group; c—MEL + NMU vs. NMU group; cc—MEL + DMBA vs. DMBA group; d—MEL + MF + NMU vs. MF + NMU group; dd—MEL + MF + DMBA vs. MF + DMBA group; e—MEL + MF + NMU vs. MEL + NMU group; ee—MEL + MF + DMBA vs. MEL + DMBA group.
β-GD, β-galactosidase; β-GR, β-glucuronidase.
NMU, N-methyl-N-nitrosourea; DMBA, dimethylbenzanthracene; MF, metformin; MEL, melatonin.
Figure 1Content of conjugated dienes (A233, nmol mg−1 protein) in the liver (A), heart (B), spleen (C) and TBARS (nmol mg−1 protein) in the liver (D), heart (E), and spleen (F) of female Sprague–Dawley rats subjected to a high-fat diet in the mammary carcinogenesis model induced by N-methyl-N-nitrosourea (NMU) or dimethylbenzanthracene (DMBA). Metformin (MF) or melatonin (MEL) was administered alone and in combination (MF + MEL). Data are expressed as means ± S.D. Significant differences P < 0.05 are designated as follows: a—NMU group vs. control group; aa—DMBA group vs. control group; b—MF + NMU vs. NMU group; bb—MF + DMBA vs. DMBA group; c—MEL + NMU vs. NMU group; cc—MEL + DMBA vs. DMBA group; d—MEL + MF + NMU vs. MF + NMU group; dd—MEL + MF + DMBA vs. MF + DMBA group; e—MEL + MF + NMU vs. MEL + NMU group; ee—MEL + MF + DMBA vs. MEL + DMBA group. NMU, N-methyl-N-nitrosourea; DMBA, dimethylbenzanthracene; MF, metformin; MEL, melatonin.
Figure 2Superoxide dismutase activity (U mg−1 protein) in the liver (A), heart (B), spleen (C) and catalase activity (μmol min−1·mg−1 protein) in the liver (D), heart (E) and spleen (F) of female Sprague–Dawley rats subjected to a high-fat diet in the mammary carcinogenesis model induced by N-methyl-N-nitrosourea (NMU) or dimethylbenzanthracene (DMBA). Metformin (MF) or melatonin (MEL) was administrated alone and in combination (MF + MEL). Data are expressed as means ± S.D. Significant differences P < 0.05 are designated as follows: a—NMU group vs. control group; aa—DMBA group vs. control group; b—MF + NMU vs. NMU group; bb—MF + DMBA vs. DMBA group; c—MEL + NMU vs. NMU group; cc—MEL + DMBA vs. DMBA group; d—MEL + MF + NMU vs. MF + NMU group; dd—MEL + MF + DMBA vs. MF + DMBA group; e—MEL + MF + NMU vs. MEL + NMU group; ee—MEL + MF + DMBA vs. MEL + DMBA group. NMU, N-methyl-N-nitrosourea; DMBA, dimethylbenzanthracene; MF, metformin; MEL, melatonin.
Figure 3Glutathione reductase activity (nmol NADPH2·min−1·mg−1 protein) in the liver (A), heart (B) and spleen (C) and glutathione peroxidase activity (nmol GSH ·min−1·mg−1 protein) in the liver (D), heart (E) and spleen (F) of female Sprague–Dawley rats subjected to a high-fat diet in the mammary carcinogenesis model induced by N-methyl-N-nitrosourea (NMU) or dimethylbenzanthracene (DMBA). Metformin (MF) or melatonin (MEL) was administrated alone and in combination (MF + MEL). Data are expressed as means ± S.D. Significant differences P < 0.05 are designated as follows: a—NMU group vs. control group; aa—DMBA group vs. control group; b—MF + NMU vs. NMU group; bb—MF + DMBA vs. DMBA group; c—MEL + NMU vs. NMU group; cc—MEL + DMBA vs. DMBA group; d—MEL + MF + NMU vs. MF + NMU group; dd—MEL + MF + DMBA vs. MF + DMBA group; e—MEL + MF + NMU vs. MEL + NMU group; ee—MEL + MF + DMBA vs. MEL + DMBA group. NMU, N-methyl-N-nitrosourea; DMBA, dimethylbenzanthracene; MF, metformin; MEL, melatonin.